在线日韩日本国产亚洲丨少妇伦子伦情品无吗丨欧美性猛交xxxx免费看蜜桃丨精品人妻系列无码一区二区三区丨亚洲精品无码不卡在线播放

Your Good Partner in Biology Research

Recombinant Human A disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13), partial

  • 中文名稱:
    Recombinant Human A disintegrin and metalloproteinase with thrombospondin motifs 13(ADAMTS13) ,partial
  • 貨號:
    CSB-YP748481HU
  • 規格:
  • 來源:
    Yeast
  • 其他:
  • 中文名稱:
    Recombinant Human A disintegrin and metalloproteinase with thrombospondin motifs 13(ADAMTS13) ,partial
  • 貨號:
    CSB-EP748481HU
  • 規格:
  • 來源:
    E.coli
  • 其他:
  • 中文名稱:
    Recombinant Human A disintegrin and metalloproteinase with thrombospondin motifs 13(ADAMTS13) ,partial
  • 貨號:
    CSB-EP748481HU-B
  • 規格:
  • 來源:
    E.coli
  • 共軛:
    Avi-tag Biotinylated

    E. coli biotin ligase (BirA) is highly specific in covalently attaching biotin to the 15 amino acid AviTag peptide. This recombinant protein was biotinylated in vivo by AviTag-BirA technology, which method is BriA catalyzes amide linkage between the biotin and the specific lysine of the AviTag.

  • 其他:
  • 中文名稱:
    Recombinant Human A disintegrin and metalloproteinase with thrombospondin motifs 13(ADAMTS13) ,partial
  • 貨號:
    CSB-BP748481HU
  • 規格:
  • 來源:
    Baculovirus
  • 其他:
  • 中文名稱:
    Recombinant Human A disintegrin and metalloproteinase with thrombospondin motifs 13(ADAMTS13) ,partial
  • 貨號:
    CSB-MP748481HU
  • 規格:
  • 來源:
    Mammalian cell
  • 其他:

產品詳情

  • 純度:
    >85% (SDS-PAGE)
  • 基因名:
  • Uniprot No.:
  • 別名:
    A disintegrin and metalloproteinase with thrombospondin motifs 13; A disintegrin like and metalloprotease (reprolysin type) with thrombospondin type 1 motif 13; A disintegrin like and metalloprotease with thrombospondin type 1 motif 13; ADAM metallopeptidase with thrombospondin type 1 motif 13; ADAM TS; ADAM-TS 13; ADAM-TS13; ADAMTS 13; ADAMTS-13; ADAMTS13; ADAMTS13 protein; ATS13_HUMAN; C9orf8; TTP; Von Willebrand factor cleaving protease; von Willebrand factor-cleaving protease; vWF cleaving protease; vWF CP; vWF-cleaving protease; vWF-CP; vWFCP
  • 種屬:
    Homo sapiens (Human)
  • 蛋白長度:
    Partial
  • 蛋白標簽:
    Tag?type?will?be?determined?during?the?manufacturing?process.
    The tag type will be determined during production process. If you have specified tag type, please tell us and we will develop the specified tag preferentially.
  • 產品提供形式:
    Lyophilized powder
    Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
  • 復溶:
    We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
  • 儲存條件:
    Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
  • 保質期:
    The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
    Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
  • 貨期:
    Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
    Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.
  • 注意事項:
    Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
  • Datasheet :
    Please contact us to get it.

產品評價

靶點詳情

  • 功能:
    Cleaves the vWF multimers in plasma into smaller forms thereby controlling vWF-mediated platelet thrombus formation.
  • 基因功能參考文獻:
    1. acute myeloid leukemia patients with low activity of ADAMTS-13 had worse prognosis after bone morrow transplantation. PMID: 30322352
    2. The Plasma Levels of ADAMTS-13, von Willebrand Factor, VWFpp, and Fibrin-Related Markers in Patients With Systemic Sclerosis Having Thrombosis PMID: 29130325
    3. The aim of the study was to investigate the role of von Willebrand factor (vWF), the vWF-cleaving protease, ADAMTS13, the composition of thrombus, and patient outcome following mechanical cerebral artery thrombectomy in patients with acute ischemic stroke. PMID: 29887594
    4. ADAMTS 1, 4, 12, and 13 levels in the maternal and cord blood were lower in the preeclampsia group than in the control group. ADAMTS 1, 4, and 12 levels in placental tissues were higher in the preeclampsia group. PMID: 29135310
    5. Decreased ADAMTS-13 activity was found in patients with proliferative lupus nephritis, and plasma ADAMTS-13 activity was closely associated with renal injury indices. PMID: 28786769
    6. These results suggest that highly elevated plasma VWF might accelerate platelet thrombus formation not only in the circulation but also on the surface of vascular endothelial cells in the setting of ADAMTS13 deficiency in Upshaw-Schulman syndrome. PMID: 29040872
    7. Prothrombotic state and systemic inflammation status might contribute to explaining the high incidence of concealed chronic renal failure in COPD, and plasma ADAMTS-13 levels may serve as a strong predictor. PMID: 29255356
    8. VWF, GMP-140, ADAMTS13 and the cerebral vasospasm, delayed cerebral ischemia, tumor diameter and prognosis of aneurysmal subarachnoid hemorrhage patients are closely related PMID: 29077161
    9. The levels of ADAMTS13 among neonates were higher as compared with healthy adults, despite a significant elevation of VWF antigen (Ag) and Ristocetin cofactor (RiCof) noted in all neonates. PMID: 28087247
    10. investigated the roles of ADAMTS13 and VWF in thrombotic events of patients with Connective Tissue Diseases PMID: 26759371
    11. Studied the significance of the von Willebrand factor (VWF)/ ADAMTS-13 ratio in advanced non-small-cell lung cancer (NSCLC). Findings suggest that the imbalance between VWF secretion and ADAMTS-13 may play a role in the hypercoagulability state in advanced NSCLC, and increase of the plasma VWF/ADAMTS-13 ratio may serve as an independent predictive factor for mortality in patients with advanced NSCLC. PMID: 28374895
    12. vaso-occlusive crisis in sickle cell disease is associated with increased reactivity of VWF, without a pronounced ADAMTS-13 deficiency PMID: 28457019
    13. The endogenous plasmin activation alone is not sufficient to cause Thrombotic thrombocytopenic purpura (TTP), but plasmin activation with ADAMTS13 deficiency might increase the risk of TTP onset. PMID: 29228282
    14. the N-linked glycans of ADAMTS-13 play a crucial role in regulating ADAMTS-13 activity PMID: 28370891
    15. Complex VWF-ADAMTS13-mediated mechanisms disturb haemostasis in inflammatory bowel disease. PMID: 28765701
    16. Missense variant in ADAMTS13 gene in a patient with NCIPH decreases secretion and activity of ADAMTS13 protein. PMID: 28980147
    17. Deficiency of the von Willebrand factor-cleaving protease ADAMTS13 is central to the pathophysiology of thrombotic thrombocytopenic purpura. Reviewed is the evidence emerged from epidemiological studies of an inverse relationship between the plasma levels of ADAMTS13 and the risk of acute coronary syndrome. [review] PMID: 28521259
    18. Data indicate that in cultured endothelial cells, one role of endogenous ADAMTS-13 is regulation of angiogenesis, mediated through VEGF and AKT signaling pathway. PMID: 28546076
    19. ADAMTS13 haplotype had an independent protective effect on CAD and genetic variation of vWF V1565L polymorphism modulates ADAMTS13 activity. PMID: 27536857
    20. The relative deficiency of plasma ADAMTS13 activity in subarachnoid haemorrhage patients may associate with worse outcome. PMID: 28102428
    21. Low ADAMTS13 was associated with increased mortality in patients with severe sepsis and septic shock and was comparable to APACHE II scores for predicting mortality. PMID: 28447577
    22. These observations support the hypothesis that a significantly reduced ADAMTS13/VWF ratio in the coronary artery flow plays a pathogenic role in acute coronary syndromes (ACS) and suggest that transition from laminar to turbulent flow at sites of coronary stenosis further enhances VWF activation and deposition. PMID: 27034431
    23. Low ADAMTS-13 activity is associated with an increased risk of coronary heart disease in the elderly, independently of VWF and established cardiovascular risk factors PMID: 27559008
    24. As folding stability was progressively disrupted, proteolysis by ADAMTS13 increased. Due to the range of folding stabilities and wide distribution of VWF A2 domain mutations studied, we conclude that these mutations disrupt regulated folding of the VWF A2 domain PMID: 29186156
    25. The 'closed' conformation of ADAMTS-13 restricts its specificity and protects against fibrinogenolysis PMID: 27514025
    26. Our results indicate that the secondary TMA syndrome and its poor outcome is characterized by relative ADAMTS13 deficiency, inflammation, and complement activation with consumption via the classical and alternative pathways. PMID: 27771173
    27. Diagnosis of thrombotic thrombocytopenic purpura among patients with ADAMTS13 Activity 10%-20. PMID: 28815685
    28. Rare genetic variants in the ADAMTS13 on Willebrand factor-binding domain contribute to pediatric stroke. PMID: 27412500
    29. No correlation was found between VWF/ADAMTS13 and infarct size in patients. Patients suffering from intramyocardial hemorrhage had significantly higher VWF activity and lower ADAMTS13 activity. Intracoronary administration of rADAMTS13 did not decrease infarct size or IMH in a porcine model of myocardial ischaemia-reperfusion, disputing the idea that the imbalance in ADAMTS13 and VWF as the cause of no reflow. PMID: 27174213
    30. both in acute and chronic cerebrovascular disease patients, ADAMTS13 levels were significantly decreased, with the lowest ADAMTS13 levels found in acute stroke patients. This difference was even more distinct when the ratio of VWF:ADAMTS13 was considered. These results demonstrate the potentially important involvement of the VWF/ADAMTS13 axis in ischemic stroke. PMID: 28591212
    31. Placental trophoblasts and villous vessel endothelial cells produce a full-length and functional ADAMTS13 protease. Placental expression of ADAMTS13 exhibits a dynamic change during pregnancy, which seems to be inhibited in late pregnancy and in patients with severe preeclampsia. PMID: 28751574
    32. ADAMTS13 activity appears to be an independent risk factor for incident prediabetes and type 2 diabetes. PMID: 27787621
    33. both anti-ADAMTS13 IgG antibody and ADAMTS13 antigen levels correlate with outcome in thrombotic thrombocytopenic purpura with increased cardiac and neurological involvement and increased mortality. PMID: 28576877
    34. Low ADAMTS-13 levels correlated with high levels of NTproBNP but had no independent prognostic significance. In conclusion, high VWF:Ag levels, probably representing endothelial dysfunction, are associated with prognosis in patients with AL amyloidosis, independently of other features of the disease or cardiac biomarkers. PMID: 27166361
    35. findings highlight the complexity of glycan modifications on ADAMTS13, which may have implications for its interaction with immune- or clearance receptors containing carbohydrate recognition domains. PMID: 27574189
    36. ADAMTS-13 levels are decreased in plasma of AML patients and the level of ADAMTS-13 is related to inflammation and infection of AML patients. Besides, low ADAMTS-13 level is one potential risk factor for AML PMID: 28033504
    37. these results demonstrate that HNPs1-3 may be potent inhibitors of ADAMTS13 activity, likely by binding to the central A2 domain of VWF and physically blocking ADAMTS13 binding. PMID: 27207796
    38. Three Single Nucleotide Variants (p.Val154Ile, p.Asp187His and p.Arg421Cys) showed reduced ex vivo and in vitro ADAMTS13 levels. However, the low frequency of these variants makes it difficult to confirm their association with Deep Vein Thrombosis. PMID: 27802307
    39. ADAMTS13 activity and VWF:Ag levels are both associated with an increased risk of all-cause and cardiovascular mortality. PMID: 27737864
    40. These findings support an ADAMTS13 activation model in which VWF D4-CK engages the TSP8-CUB2 domains, inducing the conformational change that disrupts the CUB1-spacer domain interaction and thereby activates ADAMTS13 PMID: 28209710
    41. Three cases of systemic lupus erythematosus with ADAMTS13 inhibitor-negative thrombotic microangiopathy were successfully treated with combination of mycophenolate mofetil, plasma exchange and steroid. [case reports] PMID: 27416846
    42. The pregnancy loss rate does not appear to be affected by both ADAMTS-13 and ADAMTS-19. PMID: 28088271
    43. Two novel ADAMTS13 mutations (p.I143T and p.Y570C) identified in two adolescence onset congenital thrombotic thrombocytopenic purpura patients were studied. Proteasome degradation of these ADAMTS13 mutants contributed to their reduced secretion. PMID: 27665541
    44. Correlation between ADAMTS13 activity and neurological impairment in acute thrombotic microangiopathy patients. PMID: 27379499
    45. review to introduce the state of progress with respect to some of the theorized roles of ADAMTS13[review] PMID: 27696191
    46. IL-8, TNF-alpha, tissue factor, IL-8+tissue factor and TNF-alpha+tissue factor decreased the levels of ADAMTS13 secreted by umbilical vein endothelial cells. PMID: 27766025
    47. Significantly lower ADAMTS-13 levels and significantly higher VWF antigen levels were concluded to be the result of a pathological process rather than an etiological factor for Venous thromboembolism. PMID: 26872106
    48. ADAMTS13 and VWF are co-expressed in microvascular endothelial cells. PMID: 26366828
    49. ADAMTS13-a disintegrin-like metalloproteinase with thrombospondin motif type 1 member 13-regulates a key physiological process of coagulation in the circulation by cleaving VWF multimers into small, inactive fragments. Low levels of ADAMTS13 in the blood may play a role in cardiovascular and hematological disorders, and clarifying its role may help improve disease management. PMID: 27746209
    50. ADAMTS13 activity, d-Dimer and cystatin C are associated with retinopathy in type 1 diabetic patients and are promising biomarkers for the diagnosis and monitoring of diabetic retinopathy PMID: 27208743

    顯示更多

    收起更多

  • 相關疾病:
    Thrombotic thrombocytopenic purpura congenital (TTP)
  • 亞細胞定位:
    Secreted. Note=Secretion enhanced by O-fucosylation of TSP type-1 repeats.
  • 組織特異性:
    Plasma. Expressed primarily in liver.
  • 數據庫鏈接:

    HGNC: 1366

    OMIM: 274150

    KEGG: hsa:11093

    STRING: 9606.ENSP00000360997

    UniGene: Hs.131433



主站蜘蛛池模板: 国产农村妇女高潮大叫| 日日躁夜夜躁狠狠躁| 特级a欧美做爰片三人交| 亚欧成人中文字幕一区| 美女网站免费福利视频| 国产精品久久久久久久免费看| 国产欧美综合一区二区三区| 成 人色 网 站 欧美大片在线观看| 亚洲制服丝袜自拍中文字幕| 国产人妻人伦精品久久久| 色偷偷色噜噜狠狠成人免费视频| 人妻人人做人做人人爱| 亚洲国产欧美一区点击进入| 无码精品人妻一区二区三区av | 国产精品人成视频免费播放| 少妇做爰免费视频了| 久久久久久国产精品无码超碰 | 婷婷丁香五月缴情视频| 日韩欧美亚洲综合久久| 无码尹人久久相蕉无码| 亚洲高潮喷水无码av电影| 吃奶呻吟张开双腿做受在线播放| 亚洲日本va午夜中文字幕一区| 亚洲精品久久国产高清情趣图文| 色欲人妻aaaaaa无码| 动漫无遮挡h纯肉亚洲资源大片| 全部孕妇毛片丰满孕妇孕交| 欲色影视天天一区二区三区色香欲| 久久久久久无码精品人妻a片软件| 久久精品人妻中文系列| 又爽又黄又无遮挡的视频| 人妻系列无码专区久久五月天| 久久亚洲人成电影网| 人妻av无码中文专区久久 | 久久久久久久久久久国产 | а天堂中文地址在线| 国内精品免费久久久久软件| 欧美人与动性行为视频| 国产69精品久久久久人妻| 99久久久无码国产精品秋霞网| 亚洲欧美日韩综合一区在线|